Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine.
Synonyms
Ticlopidinum
Ticlopidine
Ticlopidine hydrochloride
Ticlopidina
Brand Names
Ticlopidine Hydrochloride
Sandoz Ticlopidine
PMS-ticlopidine
Teva-ticlopidine
Ticlid 250mg Tablets
Ticlopidine hydrochloride
Ticlopidine-250
Dom-ticlopidine
Ticlid Tab 250mg
Ticlid
Mylan-ticlopidine
Ticlopidine
Alti-ticlopidine - Tab 250mg
Indication
Used in patients, who have had a stroke or stroke precursors and who cannot take aspirin or aspirin has not worked, to try to prevent another thrombotic stroke.
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
